Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Cytometry B Clin Cytom. 2023 May;104(3):224-242. doi: 10.1002/cyto.b.22097. Epub 2022 Nov 2.
Flow cytometry has been indispensable in diagnosing B cell lymphoma and plasma cell neoplasms. The advances in novel multicolor flow cytometry have also made this technology a robust tool for monitoring minimal/measurable residual disease in chronic lymphocytic leukemia and multiple myeloma. However, challenges using conventional gating strategies to isolate neoplastic B or plasma cells are emerging due to the rapidly increasing number of antibody therapeutics targeting single or multiple classic B/plasma cell-lineage markers, such as CD19, CD20, and CD22 in B cells and CD38 in plasma cells. This review is the first of a two-part series that summarizes the most current targeted therapies used in B and plasma cell neoplasms and proposes detailed alternative approaches to overcome post-targeted therapy analysis challenges by flow cytometry. The second review in this series (Chen et al.) focuses on challenges encountered in the use of targeted therapy in precursor B cell neoplasms.
流式细胞术在诊断 B 细胞淋巴瘤和浆细胞瘤方面不可或缺。新型多色流式细胞术的进步也使该技术成为监测慢性淋巴细胞白血病和多发性骨髓瘤微量/可测量残留疾病的有力工具。然而，由于针对单个或多个经典 B/浆细胞谱系标志物（如 B 细胞中的 CD19、CD20 和 CD22 以及浆细胞中的 CD38）的抗体治疗药物数量迅速增加，使用传统门控策略分离肿瘤性 B 或浆细胞的方法正面临挑战。这篇综述是两部分系列的第一部分，总结了 B 细胞和浆细胞瘤中使用的最新靶向治疗方法，并提出了详细的替代方法来克服流式细胞术分析后靶向治疗的挑战。本系列的第二篇综述（Chen 等人）重点介绍了在使用前体 B 细胞肿瘤的靶向治疗时遇到的挑战。
